» Articles » PMID: 34201951

Marine Actinomycetes, New Sources of Biotechnological Products

Overview
Journal Mar Drugs
Publisher MDPI
Specialties Biology
Pharmacology
Date 2021 Jul 2
PMID 34201951
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

The Actinomycetales order is one of great genetic and functional diversity, including diversity in the production of secondary metabolites which have uses in medical, environmental rehabilitation, and industrial applications. Secondary metabolites produced by actinomycete species are an abundant source of antibiotics, antitumor agents, anthelmintics, and antifungals. These actinomycete-derived medicines are in circulation as current treatments, but actinomycetes are also being explored as potential sources of new compounds to combat multidrug resistance in pathogenic bacteria. Actinomycetes as a potential to solve environmental concerns is another area of recent investigation, particularly their utility in the bioremediation of pesticides, toxic metals, radioactive wastes, and biofouling. Other applications include biofuels, detergents, and food preservatives/additives. Exploring other unique properties of actinomycetes will allow for a deeper understanding of this interesting taxonomic group. Combined with genetic engineering, microbial experimental evolution, and other enhancement techniques, it is reasonable to assume that the use of marine actinomycetes will continue to increase. Novel products will begin to be developed for diverse applied research purposes, including zymology and enology. This paper outlines the current knowledge of actinomycete usage in applied research, focusing on marine isolates and providing direction for future research.

Citing Articles

Advances in actinobacteria-based bioremediation: mechanistic insights, genetic regulation, and emerging technologies.

Makarani N, Kaushal R Biodegradation. 2025; 36(2):24.

PMID: 40085365 DOI: 10.1007/s10532-025-10118-4.


Dual graph-embedded fusion network for predicting potential microbe-disease associations with sequence learning.

Wu J, Xiao L, Fan L, Wang L, Zhu X Front Genet. 2025; 16:1511521.

PMID: 40008230 PMC: 11850361. DOI: 10.3389/fgene.2025.1511521.


Metabolomic and genomic insights into Micromonospora carbonacea subsp. caeruleus for anti-colorectal compound.

Kongsaya T, Emthomya N, Ngamcharungchit C, Aroonsri A, Uawisetwathana U, Pruksatrakul T Appl Microbiol Biotechnol. 2025; 109(1):50.

PMID: 39998653 PMC: 11861244. DOI: 10.1007/s00253-025-13427-z.


Marine actinobacteria metabolites: unlocking new treatments for acne vulgaris.

De La Hoz-Romo M, Diaz L, Gomez-Leon J, Quintero M, Villamil L Front Microbiol. 2025; 15():1501951.

PMID: 39834363 PMC: 11743623. DOI: 10.3389/fmicb.2024.1501951.


Unveiling metabolo-genomic insights of potent antitumoral and antibiotic activity in sp. VB1 from Valparaíso Bay.

Serna-Cardona N, Zamora-Leiva L, Sanchez-Carvajal E, Claverias F, Cumsille A, Penton K Front Microbiol. 2024; 15:1463911.

PMID: 39417076 PMC: 11479970. DOI: 10.3389/fmicb.2024.1463911.


References
1.
Baltz R . Strain improvement in actinomycetes in the postgenomic era. J Ind Microbiol Biotechnol. 2011; 38(6):657-66. DOI: 10.1007/s10295-010-0934-z. View

2.
Pereira F, Almeida J, Paulino M, Grilo I, Macedo H, Cunha I . Antifouling Napyradiomycins from Marine-Derived Actinomycetes . Mar Drugs. 2020; 18(1). PMC: 7024211. DOI: 10.3390/md18010063. View

3.
Anteneh Y, Franco C . Whole Cell Actinobacteria as Biocatalysts. Front Microbiol. 2019; 10:77. PMC: 6387938. DOI: 10.3389/fmicb.2019.00077. View

4.
McDonald M . Microbial Experimental Evolution - a proving ground for evolutionary theory and a tool for discovery. EMBO Rep. 2019; 20(8):e46992. PMC: 6680118. DOI: 10.15252/embr.201846992. View

5.
Eiler A, Zaremba-Niedzwiedzka K, Martinez-Garcia M, McMahon K, Stepanauskas R, Andersson S . Productivity and salinity structuring of the microplankton revealed by comparative freshwater metagenomics. Environ Microbiol. 2013; 16(9):2682-98. PMC: 4253090. DOI: 10.1111/1462-2920.12301. View